SGLT2 Inhibitors Lawsuit: NY Injury Claims Explained

Lawsuits allege that SGLT2 inhibitors such as Invokana, Farxiga, and Jardiance caused lower-limb amputations, diabetic ketoacidosis (DKA), acute kidney injury, and Fournier’s gangrene. Manufacturers have faced claims that they failed to adequately warn patients and prescribing physicians of these serious risks. If you suffered one of these injuries in New York, you may have a product liability claim against the drug manufacturer.

New York’s statute of limitations for personal injury product liability claims is three years from the date of injury under CPLR §214. The clock typically begins running when you were harmed or reasonably discovered the connection between the drug and your injury. Because drug injury cases often involve complex causation questions, you should consult a New York attorney as soon as possible to preserve your claim.

Liability in an SGLT2 inhibitor case may fall on the drug’s manufacturer for design defects or failure to warn, as well as distributors or pharmacies in certain circumstances. Under New York product liability law, plaintiffs can pursue claims under strict liability or negligence theories. An attorney can evaluate the facts of your case to identify all potentially responsible parties.

New York plaintiffs in drug injury lawsuits may seek damages for medical expenses (past and future), lost wages and earning capacity, pain and suffering, and permanent disability or disfigurement. No specific dollar amount can be guaranteed—outcomes depend on the severity of the injury, the strength of the evidence, and other case-specific factors. An experienced NY personal injury attorney can assess what damages may apply to your situation.